Copyright
©The Author(s) 2016.
World J Transplant. Mar 24, 2016; 6(1): 125-134
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.125
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.125
Hypercholesterolemia | Hypertriglyceridemia |
Genetic predisposition | Genetic predisposition |
Age | Excessive dietary intake of carbohydrates, cholesterol, and saturated fat |
Excessive dietary intake of cholesterol and saturated fats | Obesity |
Obesity | Proteinuria |
Proteinuria | Renal insufficiency |
Anti-hypertensive agents, e.g., diuretics, beta-blockers | Corticosteroids |
Corticosteroids | Mammalian target-of-rapamycin inhibitors (sirolimus) |
Calcineurin-inhibitors (cyclosporine, possibly tacrolimus) | |
Mammalian target-of-rapamycin inhibitors (sirolimus, everolimus) |
Initial post-transplant period | Manage acute graft-related concerns |
Optimize immunosuppressive medication to graft function | |
2-3 mo post-transplant | Measure 8-12 h fasting lipid profile |
If LDL cholesterol and/or triglyceride level above target1 | Dietician consult |
2-3 mo post-dietary intervention | Measure 8-12 h fasting lipid profile |
If LDL cholesterol and/or triglyceride level still above target1 | Initiate statin therapy, e.g., atorvastatin 10 mg/d or rosuvastatin 5 mg/d |
Assess for potential drug interactions | |
Monitor creatine kinase and liver transaminase levels | |
2-3 mo post-statin initiation | Measure 8-12 h fasting lipid profile |
If LDL cholesterol and/or triglyceride level still above target1 | Repeat all of the above until targets are achieved. Increase statin dose as tolerated to a maximum acceptable dose with each measurement not at target. If targets are not achieved then consider adding a supplemental agent, e.g., ezetimibe 10 mg/d |
If LDL cholesterol and/or triglyceride level still above target1 | Consider consultation with lipid specialist |
LDL and triglyceride target levels achieved | Annual monitoring of lipid levels. Consider more frequent monitoring for side effects |
At all times post-transplant | Gauge overall cardiovascular risk |
- Citation: Agarwal A, Prasad GVR. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant 2016; 6(1): 125-134
- URL: https://www.wjgnet.com/2220-3230/full/v6/i1/125.htm
- DOI: https://dx.doi.org/10.5500/wjt.v6.i1.125